Last reviewed · How we verify

Ga-68 labeled PSMA-11 PET — Competitive Intelligence Brief

Ga-68 labeled PSMA-11 PET (Ga-68 labeled PSMA-11 PET) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: PET imaging agent. Area: Oncology.

phase 3 PET imaging agent PSMA (prostate-specific membrane antigen) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Ga-68 labeled PSMA-11 PET (Ga-68 labeled PSMA-11 PET) — University of California, San Francisco. Ga-68 labeled PSMA-11 is a positron emission tomography (PET) imaging agent that binds to prostate-specific membrane antigen (PSMA) on prostate cancer cells to enable detection and localization.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Ga-68 labeled PSMA-11 PET TARGET Ga-68 labeled PSMA-11 PET University of California, San Francisco phase 3 PET imaging agent PSMA (prostate-specific membrane antigen)
[F-18]-Fludeoxyglucose [F-18]-Fludeoxyglucose University of Saskatchewan marketed Radiopharmaceutical; PET imaging agent Glucose transporter (GLUT1); hexokinase
[Ga-68]PSMA [Ga-68]PSMA Norbert Avril, M.D. marketed PET imaging agent / radiopharmaceutical PSMA (prostate-specific membrane antigen)
Fludeoxyglucose F 18 (FDG) Fludeoxyglucose F 18 (FDG) Teva Branded Pharmaceutical Products R&D, Inc. marketed Radiopharmaceutical; PET imaging agent Glucose transporter (GLUT1); hexokinase
PET Scan with [11C]ABP688 PET Scan with [11C]ABP688 Stony Brook University marketed PET imaging agent / Radiotracer mGluR5 (metabotropic glutamate receptor 5)
Neuraceq (florbetaben 18F) Neuraceq (florbetaben 18F) Piramal Imaging Limited marketed PET imaging agent Amyloid-beta plaques
[11C]raclopride [11C]raclopride New York State Psychiatric Institute marketed Dopamine D2/D3 receptor antagonist (PET imaging agent) Dopamine D2 receptor, Dopamine D3 receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (PET imaging agent class)

  1. University of California, San Francisco · 2 drugs in this class
  2. Central Hospital, Nancy, France · 1 drug in this class
  3. Centre hospitalier de l'Université de Montréal (CHUM) · 1 drug in this class
  4. Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · 1 drug in this class
  5. Institute for Neurodegenerative Disorders · 1 drug in this class
  6. OHSU Knight Cancer Institute · 1 drug in this class
  7. Piramal Imaging Limited · 1 drug in this class
  8. SOFIE · 1 drug in this class
  9. Universidad Central del Caribe · 1 drug in this class
  10. University of California, Irvine · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ga-68 labeled PSMA-11 PET — Competitive Intelligence Brief. https://druglandscape.com/ci/ga-68-labeled-psma-11-pet. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: